Literature DB >> 31440867

MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.

Yulian Mytsyk1, Yuriy Borys1, Lesia Tumanovska2, Dmytro Stroy2, Askold Kucher3, Katarina Gazdikova4,5, Luis Rodrigo6, Peter Kruzliak7,8, Robert Prosecky9, Peter Urdzik10, Victor Dosenko2.   

Abstract

None of the currently investigated molecular markers demonstrated sufficient accuracy in prognostication of the renal cell carcinoma (RCC) oncologic outcomes; thus, none of them has been recommended for the application in the routine clinical practice. The role of miR-15a as a potential prognostic marker for RCC is still not unveiled. The aim of our study was to assess the expression of miR-15a in tumor tissues of the patients with RCC and to evaluate the possibility of its usage as a prognostic molecular biomarker of this disease. The retrospective included 64 adult patients with clear cell RCC (ccRCC) in whom radical or partial nephrectomy was conducted. After deparaffinization of formalin-fixed paraffin-embedded (FFPE) ccRCC specimens, the tissue expression of miR-15a was measured using the reverse transcription and quantitative polymerase chain reaction in the real time. For the reference, the expression of miR-15a was estimated in 15 FFPE tissue specimens of the normal renal parenchyma. Survival analysis involved all cases of non-metastatic RCCs (n = 57). Five-year cancer-specific survival (CSS) was estimated by means of the Kaplan-Meier method and was calculated from the date of surgery to the date of death. Patients with the RCC were characterized by significantly upregulated tumor tissue mean levels of miR-15a compared to the healthy controls: 0.10 ± 2.62 relative units (RU) versus 4.84E - 03 ± 3.11E - 03 RU (p < 0.001). Overexpression of miR-15a was strongly associated with poor histologic prognostic features of ccRCC. Poorly differentiated tumors tend to have more pronounced upregulation of miR-15a compared to highly differentiated lesions: Mean expression values were 4.57 ± 3.19 RU for Fuhrman grade 4 versus 0.02 ± 0.01 RU for Fuhrman grade 1 (p < 0.001). The metastatic involvement of the regional lymphatic nodules (N +) was associated with significantly upregulated miRNA-15a in comparison with N - cases: Mean expression values were 4.92 ± 2.80 RU versus 1.10 ± 2.29 RU, respectively (p < 0.001). In patients with miR-15a expression in RCC tissues ≤ 0.10 RU, mean 5-year CSS was significantly longer compared to patients with expression levels above this threshold: 92.31% (mean duration of survival-59.88 ± 0.12 months) versus 54.8% (mean duration of survival-49.74 ± 2.16 months), respectively (p < 0.001). The tissue expression of miR-15a could be used as a potential prognostic molecular biomarker for conventional RCC.

Entities:  

Keywords:  Biomarker; Cancer; Clear cell; Genetic; MicroRNA-15a; Prediction; Prognosis; Renal cell carcinoma; Survival; miRNA-15a

Mesh:

Substances:

Year:  2019        PMID: 31440867     DOI: 10.1007/s10238-019-00574-7

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  40 in total

Review 1.  Interplay between epigenetic abnormalities and deregulated expression of microRNAs in cancer.

Authors:  Ammad Ahmad Farooqi; Enrique Fuentes-Mattei; Sundas Fayyaz; Priyank Raj; Matthew Goblirsch; Palmiro Poltronieri; George A Calin
Journal:  Semin Cancer Biol       Date:  2019-02-08       Impact factor: 15.707

2.  Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.

Authors:  Zhun Wang; Shuanghe Peng; Hui Xie; Linpei Guo; Qiliang Cai; Zhiqun Shang; Ning Jiang; Yuanjie Niu
Journal:  Clin Exp Med       Date:  2018-01-23       Impact factor: 3.984

3.  Serum microRNA-15a level acts as a potential diagnostic and prognostic biomarker for human esophageal squamous cell carcinoma.

Authors:  Jialin Li; Ming Li; Feng Gao; Xiaojun Ge
Journal:  Cancer Biomark       Date:  2017       Impact factor: 4.388

4.  Downregulation of miR-221, -30d, and -15a contributes to pathogenesis of prostate cancer by targeting Bmi-1.

Authors:  Hanqing Xuan; Wei Xue; Jiahua Pan; Jianjun Sha; Baijun Dong; Yiran Huang
Journal:  Biochemistry (Mosc)       Date:  2015-03       Impact factor: 2.487

Review 5.  Is miR-34a a Well-equipped Swordsman to Conquer Temple of Molecular Oncology?

Authors:  Ammad Ahmad Farooqi; Sundas Fayyaz; Iryna Shatynska-Mytsyk; Zeeshan Javed; Saima Jabeen; Ilhan Yaylim; Maria Luisa Gasparri; Pierluigi Benedetti Panici
Journal:  Chem Biol Drug Des       Date:  2016-01-13       Impact factor: 2.817

6.  External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.

Authors:  Richard Zigeuner; Georg Hutterer; Thomas Chromecki; Arvin Imamovic; Karin Kampel-Kettner; Peter Rehak; Cord Langner; Karl Pummer
Journal:  Eur Urol       Date:  2008-11-28       Impact factor: 20.096

Review 7.  MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.

Authors:  Maria Luisa Gasparri; Zein Mersini Besharat; Ammad Ahmad Farooqi; Sumbul Khalid; Katayoun Taghavi; Raad Aris Besharat; Claudia Sabato; Andrea Papadia; Pierluigi Benedetti Panici; Michael David Mueller; Elisabetta Ferretti
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-14       Impact factor: 4.553

8.  Prognostic and clinicopathological value of Ki-67/MIB-1 expression in renal cell carcinoma: a meta-analysis based on 4579 individuals.

Authors:  Zhun Wang; Hui Xie; Linpei Guo; Qiliang Cai; Zhiqun Shang; Ning Jiang; Yuanjie Niu
Journal:  Cancer Manag Res       Date:  2017-11-21       Impact factor: 3.989

Review 9.  MicroRNA Regulation of Telomerase Reverse Transcriptase (TERT): Micro Machines Pull Strings of Papier-Mâché Puppets.

Authors:  Ammad Ahmad Farooqi; Qaisar Mansoor; Nada Alaaeddine; Baojun Xu
Journal:  Int J Mol Sci       Date:  2018-04-01       Impact factor: 5.923

Review 10.  Potential clinical applications of microRNAs as biomarkers for renal cell carcinoma.

Authors:  Yulian Mytsyk; Victor Dosenko; Michał Andrzej Skrzypczyk; Yuriy Borys; Yuriy Diychuk; Askold Kucher; Vasyl Kowalskyy; Serhyi Pasichnyk; Oleh Mytsyk; Lubov Manyuk
Journal:  Cent European J Urol       Date:  2018-07-02
View more
  2 in total

1.  Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response.

Authors:  Yulian Mytsyk; Serhiy Pasichnyk; Ihor Dutka; Ihor Dats; Dmytro Vorobets; Michał Skrzypczyk; Yerzhan Uteuliyev; Andrea Botikova; Katarina Gazdikova; Peter Kubatka; Peter Urdzik; Peter Kruzliak
Journal:  Clin Exp Med       Date:  2020-02-05       Impact factor: 3.984

2.  Determination of Exosome Mitochondrial DNA as a Biomarker of Renal Cancer Aggressiveness.

Authors:  Elena Arance; Viviana Ramírez; Alejandro Rubio-Roldan; Francisco M Ocaña-Peinado; Catalina Romero-Cachinero; Ana Belén Jódar-Reyes; Fernando Vazquez-Alonso; Luis Javier Martinez-Gonzalez; Maria Jesus Alvarez-Cubero
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.